Lacktman, Wein Quoted in mHealthIntelligence About OIG’s Approval of Free SmartPhone Giveaway for Medication Adherence Tracking
05 February 2019
mHealthIntelligence
Partner Nate Lacktman and Of Counsel Emily Wein were quoted in the mHealthIntelligence article, “OIG Oks Free Phones in mHealth Project Targeting Medication Adherence,” about the Office of the Inspector General decision to approve a digital health care company’s plan to loan free smartphones to patients enrolled in a project tracking medication adherence. The OIG last month ruled in favor of the digital health company’s plans which gives phones to patients enrolled in a digital therapeutic program in which they track medication adherence through an ingestible sensor and corresponding mobile health platform. This is the sixth time that the OIG has approved a projects like this.
Lacktman and Wein said the OIG ruled that the program did not violate anti-kickback laws for numerous reasons and also noted that the OIG’s ruling is specific to the case, but it points to support by the federal government for programs that improve access to care and health outcomes.
“OIG included its traditional disclaimer that the advisory opinion can only be relied upon by the specific company that requested it, and the opinion would be null if any material facts were not disclosed,” they wrote. “Companies offering similar digital health therapeutics or remote patient monitoring programs should closely review the opinion because it offers insight into the government’s view on how technology can promote access to care. Companies evaluating or developing similar programs offering free or discounted technology should carefully consider the safeguards enumerated in OIG’s analysis prior to launch.”
Lacktman and Wein said the OIG ruled that the program did not violate anti-kickback laws for numerous reasons and also noted that the OIG’s ruling is specific to the case, but it points to support by the federal government for programs that improve access to care and health outcomes.
“OIG included its traditional disclaimer that the advisory opinion can only be relied upon by the specific company that requested it, and the opinion would be null if any material facts were not disclosed,” they wrote. “Companies offering similar digital health therapeutics or remote patient monitoring programs should closely review the opinion because it offers insight into the government’s view on how technology can promote access to care. Companies evaluating or developing similar programs offering free or discounted technology should carefully consider the safeguards enumerated in OIG’s analysis prior to launch.”
People
Related News
04 October 2024
In the News
Rajiv Dharnidharka and Jeanette Barzelay Featured Across Legal Press for Move to Foley
Recent laterals Rajiv Dharnidharka and Jeanette Barzelay are featured across legal press for their arrival to Foley, including in the Law360 article, "Foley Adds 2 DLA Piper Business Litigators In San Francisco."
04 October 2024
In the News
Chanley Howell on AI IP Protection in Litigation – 'Judges are human'
Foley & Lardner LLP partner Chanley Howell shared insight on protecting the intellectual property behind emerging technologies like artificial intelligence in the Bloomberg Law article, "AI Put on Trial in ‘Life or Death’ Police Tech Clashes."
01 October 2024
In the News
Natasha Allen on DEI Challenges for Corporate Boards – 'Diversity is necessary for companies to succeed'
Foley & Lardner LLP partner Natasha Allen authored the article, "Navigating Today's DEI Challenges," in the November/December issue of Corporate Governance Advisor.